India first priority for Covid-19 vaccine delivery: Serum Institute | Latest News India - Hindustan Times
close_game
close_game

India first priority for Covid-19 vaccine delivery: Serum Institute

New Delhi | ByAgence France-Presse | Posted by Shivani Kumar
Nov 24, 2020 04:03 AM IST

AstraZeneca and Oxford University said Monday that their drug had proved on average 70 percent effective at stopping the virus after trying it on 23,000 people.

India will be given first priority for the delivery of the AstraZeneca/Oxford vaccine after its British developers claimed success following mass testing, the world’s largest vaccine manufacturer by volume said Monday.

India is the second worst-infected nation after the United States with more than 9.1 million virus cases.(HT photo)
India is the second worst-infected nation after the United States with more than 9.1 million virus cases.(HT photo)

The chief executive of the Serum Institute of India, Adar Poonawalla, said the manufacturer has already produced 40 million doses of the vaccine so far.

HT launches Crick-it, a one stop destination to catch Cricket, anytime, anywhere. Explore now!

“By January, we should have, you know, 100 million doses is minimum because we’ve already made 40 million doses,” Poonawalla, whose father founded the vaccine manufacturer, told television broadcaster NDTV.

Poonawalla said he expected that some 90 percent of Serum Institute’s doses were to be sold to the Indian government at around 250 rupees (US$3.00).

Also Read | Dosing error turns into lucky punch for AstraZeneca and Oxford

“Most of that 90 percent is what’s going to go to the government of India and maybe 10 percent in the private market at the higher price (of 1,000 rupees),” he said.

“We’re hoping for this emergency use licence so that by the end of December, January we can start rolling out some (doses).”

AstraZeneca and Oxford University said Monday that their drug had proved on average 70 percent effective at stopping the virus after trying it on 23,000 people.

The Oxford drug can be transported easily at normal refrigerator temperatures -- unlike some of the other candidates, which require extremely cold storage.

AstraZeneca said it planned to produce up to three billion doses of the vaccine in 2021 if it passes the remaining regulatory hurdles.

The Serum Institute in August struck a deal with Gavi, the Vaccine Alliance, to produce up to 100 million COVID-19 doses of two different potential vaccines from AstraZeneca and US biotech company Novavax.

Once the vaccines gain regulatory approval, the doses could be produced as early as the first half of 2021 for distribution to low- and middle-income countries, Gavi said.

India’s Health Minister Harsh Vardhan told India Today TV earlier Monday that he expected between 250-300 million Indians would be immunised by September next year.

First in line would be health workers, other frontline workers including the police, paramilitary and those working in sanitisation, as well as people aged above 65, Vardhan added.

Prime Minister Narendra Modi is expected to meet with state leaders on Tuesday for discussions about the distribution of the vaccine, local media reported.

India is the second worst-infected nation after the United States with more than 9.1 million virus cases.

Discover the complete story of India's general elections on our exclusive Elections Product! Access all the content absolutely free on the HT App. Download now!

Get Current Updates on India News, Ram Navami Live Updates , Lok Sabha Election 2024 live, Elections 2024, Election 2024 Date along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, April 18, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On